Cyclooxygenase-2 expression in human pituitary tumors

Cancer

Volumn 97, Issue 11, 2003, Pages 2814-2821

  Vidal, Sergio ^a,b   Kovacs, Kalman ^a   Bell, David ^a   Horvath, Eva ^a   Scheithauer, Bernd W ^c   Lloyd, Ricardo V ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Cell proliferation; Cyclooxygenase 2; Hypoxia inducible factor 1 ; Immunohistochemistry; Pituitary tumors

Indexed keywords

CYCLOOXYGENASE 2; TUMOR MARKER;

ADENOMA; ADOLESCENT; ADULT; AGE; AGED; ANGIOGENESIS; ARTICLE; CANCER INVASION; CORRELATION ANALYSIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; STAINING; TUMOR VOLUME;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KI-67 ANTIGEN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PITUITARY NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0038521395     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11387     Document Type: Article

References (55)

1. Crofford LJ. Prostaglandin biology. Gastroenterol Clin North Am. 2001;30:863-876.
2. Bishop-Bailey D, Calatayud S, Warner TD, Hla T, Mitchell JA. Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol. 2002;21:93-101.
3. Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med. 1997;216:201-210.
4. Kelley DJ, Mestre JR, Subbaramaiah K, et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis. 1997;18:795-799.
5. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30:3-21.
6. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs. 2002;13:127-137.
7. DuBois RN. Review article: cyclooxygenase - a target for colon cancer prevention. Aliment Pharmacol Ther. 2000; 14(Suppl 1):64-67.
8. Fujita H, Koshida K, Keller ET, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate. 2002;53:232-240.
9. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology. 2002;122:1800-1807.
10. Van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol. 2002;196:171-179.
11. Shamma A, Yamamoto H, Doki Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res. 2000;6:1229-1238.
12. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333-338.
13. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632-635.
14. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803-809.
15. Tiano H, Chulada P, Spalding J, et al. Effects of cyclooxygenase deficiency on inflammation and papilloma development in mouse skin. Proc Am Assoc Cancer Res. 1997;38: 1727.
16. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996;56:2556-2560.
17. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
18. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94:3336-3340.
19. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology. 2001;121:1339-1347.
20. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55:429-434.
21. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002;190: 279-286.
22. Kovacs K, Scheithauer BW, Horvath E, Lloyd RV. The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer. 1996;78: 502-510.
23. Kovacs K, Horvath E, Vidal S. Classification of pituitary adenomas. J Neurooncol. 2001;54:121-127.
24. Pernicone PJ, Scheithauer BW, Sebo TJ, et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer. 1997; 79:804-812.
25. Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch. 2001;438:595-602.
26. Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38:99-106.
27. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA. Angiogenesis in pituitary adeno. J Endocrinol. 2000;165:475-481.
28. Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JA, Harris AL. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. Br J Cancer. 2000;82:1441-1445.
29. Vidal S, Kovacs K, Horvath E, et al. Topoisomerase II alpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol. 2002;15:1205-1212.
30. Kovacs K, Lloyd R, Horvath E, et al. Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. Am J Pathol. 1989;134:345-353.
31. Kovacs K, Stefaneanu L, Horvath E, et al. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Virchows Arch A Pathol Anat Histopathol. 1991;418:439-446.
32. Vidal S, Scheithauer BW, Kovacs K. Vascularity in nontumorous human pituitaries and incidental microadenomas: a morphometric study. Endocr Pathol. 2000;11:215-227.
33. Vidal S, Horvath E, Kovacs K, Kuroki T, Lloyd RV, Scheithauer BW. Expression of hypoxia inducible factor-1α (HIF-1α) in pituitary tumors. Histol Histopathol. In press.
34. Vidal S, Roman A, Oliveira MC, De La Cruz LF, Moya L. Simultaneous localization of Pit-1 protein and gonadotropins on the same cell type in the anterior pituitary glands of the rat. Histochem Cell Biol. 1998;110:183-188.
35. Saha D, Roman C, Beauchamp RD. New strategies for colorectal cancer prevention and treatment. World J Surg. 2002; 26:762-766.
36. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11-21.
37. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 2002;122:1101-1112.
38. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6:519-525.
39. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology. 2001;58: 127-131.
40. Badawi AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Int J Oncol. 2002;20:1109-1122.
41. Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol. 2002;21:193-201.
42. Ding XZ, Tong WG, Adrian TE. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology. 2001;1:291-299.
43. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaramaiah K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann N Y Acad Sci. 2001;952:109-115.
44. Shirahama T, Arima J, Akiba S, Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer. 2001;92:188-193.
45. Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol. 2001;158:849-853.
46. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000;60:5767-5772.
47. Yang VW, Shields JM, Hamilton SR, et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res. 1998;58:1750-1753.
48. Turner HE, Wass JA. Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary. 1999;1:147-151.
49. Turner HE, Nagy Z, Esiri MM, Harris AL, Wass JA. Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab. 2000;85:2931-2935.
50. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 2001;3:53-61.
51. Dermond O, Ruegg C. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. Drug Resist Updat. 2001;4:314-321.
52. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-1311.
53. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol. 1999;10:229-235.
54. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-1α stabilization and nuclear localization in a prostate cancer cell line. J Biol Chem.
55. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular 02 tension. Proc Natl Acad Sci USA. 1995;92:5510-5514.